Previous analyses of the 2 BENCHMRK studies of raltegravir (RAL) vs placebo (Pbo) plus optimized background therapy (OBT) in treatment-experienced HIVinfected patients (pts) by PSS as contributed by OBT used assumptions of susceptibility to DRV/r based on prior use, since commercial phenotyping was not available. Re-analysis is now performed using newly available DRV/r phenotype data.
Purpose of the study Previous analyses of the 2 BENCHMRK studies of raltegravir (RAL) vs placebo (Pbo) plus optimized background therapy (OBT) in treatment-experienced HIVinfected patients (pts) by PSS as contributed by OBT used assumptions of susceptibility to DRV/r based on prior use, since commercial phenotyping was not available. Re-analysis is now performed using newly available DRV/r phenotype data.
Methods
In BENCHMRK pts who used DRV/r in OBT, baseline PSS was recalculated using the DRV/r PhenoSense® result (Monogram Bioscience). A new analysis by PSS score of RNA <50c/mL for wk 48 and wk 156 was performed using the upper clinical cutoff (UC) of OBTs, including DRV/r. An exploratory analysis compared outcomes for pts whose only fully active ART was RAL or DRV/r.
Results
184 pts in the RAL group and 99 in Pbo group used DRV/r in OBT at study entry; of these 166 and 90 pts, respectively, had no prior use of DRV/r and were previously considered DRV/r susceptible. 165 pts in the RAL group and 91 in Pbo group had baseline DRV/r Phenosense results: 7% and 7% of pts previously assumed susceptible to DRV/r showed phenotypic resistance; 17% and 44% assumed resistant to DRV/r were found to be susceptible. Overall results at wk 48 were 64% vs 34% with RNA<50c/mL for RAL vs Pbo. Wk 48 virologic outcomes by PSS score are shown in table 1. Wk 156 outcomes by PSS were consistent (not shown). In the 1 Universitat Bonn, Bonn-Venusberg, Germany Full list of author information is available at the end of the article Table 1 Efficacy at week 48, RNA<50 copies/mL %, (n/N) 
Conclusions
In BENCHMRK, prior use of DRV predicted DRV susceptibility similarly to the UC phenotypic criteria. Reanalysis of virologic responses by PSS score incorporating the UC Phenosense result for DRV/r demonstrated consistent treatment differences between RAL and Pbo groups for all PSS scores, generally similar to the earlier analyses. In an exploratory analysis approximating a direct comparison of RAL vs DRV/r as sole active agents, virologic responses using UC appeared higher for RAL than DRV at both time points, although numbers of pts receiving DRV monotherapy were small. 
